GlassScriptPhysician profile
Anuradha Singh
NPI 1700318136
$11,000.51
in general payments reported to CMS, 2019-2025
26 companies · $4,775 in 2025
The $4,775 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $173 · 2023: $1,433 · 2024: $4,619 · 2025: $4,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,476 · Food and Beverage: $3,831 · Consulting Fee: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,476.00 |
| Food and Beverage | $3,831.03 |
| Consulting Fee | $520.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $7,128.06 | 2022-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $1,145.71 | 2023-2025 | |
| Celgene Corporation | $1,075.11 | 2022-2025 | Zeposia |
| Emd Serono, INC. | $378.50 | 2023-2025 | Mavenclad |
| Biogen, INC. | $349.46 | 2023-2025 | Vumerity, Tysabri |
| Horizon Therapeutics Plc | $252.56 | 2023 | Uplizna |
| Genentech USA, INC. | $105.41 | 2022-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Amgen INC. | $93.90 | 2024-2025 | Uplizna |
| Abbvie INC. | $68.91 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $44.74 | 2025 | Ponvory |
| Averitas Pharma INC. | $36.30 | 2025 | Qutenza |
| Lilly USA, LLC | $33.74 | 2023-2025 | Kisunla, Reyvow, Emgality |
| Argenx US, INC. | $33.10 | 2023-2025 | Vyvgart Hytrulo |
| Cycle Pharmaceuticals INC | $32.45 | 2024-2025 | Tascenso Odt, Bafiertam |
| Amneal Pharmaceuticals LLC | $29.88 | 2025 | Crexont |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $24.41 | 2023 | Ocrevus |
| Genzyme Corporation | $22.19 | 2023 | |
| Philips North America LLC | $20.88 | 2024 | (Ak6) Vest Therapy |
| Mallinckrodt Hospital Products INC. | $19.88 | 2025 | Acthar |
| Harmony Biosciences LLC | $17.83 | 2023 | Wakix |
| Sk Life Science, INC. | $15.94 | 2022 | |
| Kedrion Biopharma, INC. | $15.46 | 2025 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Teva Pharmaceuticals USA, INC. | $14.84 | 2024 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $14.03 | 2025 | |
| Lundbeck LLC | $13.74 | 2024 | Vyepti |
| Merz Pharmaceuticals, LLC | $13.48 | 2024 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuradha Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.